CorMedix

CRMD

Market cap $773M

CorMedix delivered strong Q3 results, with DefenCath outperforming expectations and near-term earnings power underestimated in prior analysis. CRMD raised FY25 guidance, but long-term risks remain due to TDAPA reimbursement changes, pricing pressure, and customer concentration. The Melinta acquisition and Rezzayo prophylaxis trial offer growth optionality, but Rezzayo's success is uncertain and pivotal for post-TDAPA prospects.

Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2025 financial results and provided a corporate update.

CorMedix Inc. (NASDAQ:CRMD) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents.

CorMedix Inc. ( CRMD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Joseph Todisco - CEO & Director Elizabeth Masson-Hurlburt - Executive VP, Chief Operating Officer & Chief Integration Officer Susan Blum - EVP & Chief Financial Officer Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Leszek Sulewski - Truist Securities, Inc., Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Presentation Operator Good day, and welcome to the CorMedix Third Quarter 2025 Earnings and Corporate Update Conference Call.

‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J.

The mean of analysts' price targets for CorMedix (CRMD) points to an 80.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.

CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CRMD, GWRE, TNET, UHS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on Nov. 4, 2025.

BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2025, before the market opens on Wednesday, November 12, 2025, and will host a corporate update conference call at 8:30am Eastern Time.